All In Biotech

Drug Trial Radar · NCT04152200

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)

Last checked: Nov 20, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

21

Actual

Start

Jan 21, 2020

Primary completion

May 18, 2021

Study completion Jun 23, 2025

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Nov 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).

Conditions

  • Primary Hyperoxaluria Type 1
  • Primary Hyperoxaluria

Interventions

  • LumasiranDrug

    Lumasiran will be administered by subcutaneous (SC) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Percent Change in Plasma Oxalate From Baseline to Month 6Time frame: Baseline to Month 6
  2. Cohort B: Percent Change in Pre-dialysis Plasma Oxalate From Baseline to Month 6Time frame: Baseline to Month 6

Locations

14 sites in 11 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    Garran, Australia

  • Clinical Trial Site

    Brussels, Belgium

  • Clinical Trial Site

    Bron, France

  • Clinical Trial Site

    Lyon, France

  • Clinical Trial Site

    Haifa, Israel

  • Clinical Trial Site

    Nahariya, Israel

  • Clinical Trial Site

    Rome, Italy

  • Clinical Trial Site

    Irbid, Jordan

  • Clinical Trial Site

    Beirut, Lebanon

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    Yenimahalle, Turkey (Türkiye)

  • Clinical Trial Site

    Dubai, United Arab Emirates

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.